---
figid: PMC9303316__BCP-88-2875-g001
pmcid: PMC9303316
image_filename: BCP-88-2875-g001.jpg
figure_link: /pmc/articles/PMC9303316/figure/bcp15191-fig-0003/
number: FIGURE 3
figure_title: ''
caption: Drug target MR effects of IL‐6 and IL‐6R on clinical outcome, per 1 mg/L
  reduction in CRP. Forest plots representing the risk of clinical outcome parameters
  for all genetic instruments, scaled to a 1 mg/L reduction in CRP levels. The hash
  mark indicates an association of the genetic instrument with the clinical outcome
  that meets the multiple testing threshold (8.92 × 10−4)
article_title: 'Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian
  randomization study on both IL6 and IL6R .'
citation: Arjen J. Cupido, et al. Br J Clin Pharmacol. 2022 Jun;88(6):2875-2884.
year: '2022'

doi: 10.1111/bcp.15191
journal_title: British Journal of Clinical Pharmacology
journal_nlm_ta: Br J Clin Pharmacol
publisher_name: John Wiley and Sons Inc.

keywords:
- cardiovascular disease
- classical signalling
- IL‐6
- trans‐signalling

---
